Xspray Pharma publishes its Annual Report 2023

Regulatory press release 2024-03-27

Xspray Pharma AB (publ) today publishes its Annual Report for the financial year 2023. The Annual Report is attached to this press release and available on the company’s website: https://xspraypharma.com/investors/financial-reports/

An extract from the CEO-letter from Per Andersson, CEO of Xspray Pharma:
 
“Throughout 2023, we continued to make significant progress on the exciting journey toward the launch of our product Dasynoc®. The settlement with Bristol Myers Squibb (BMS) in the patent dispute over Dasynoc® was a crucial milestone for the company, paving the way for the launch of our product in the beginning of September 2024 pending final FDA approval. We are working diligently to ensure a successful market launch of Dasynoc®.”

For further information, please contact:

Kerstin Hasselgren
Senior Advisor & Investor Relations
Xspray Pharma AB
Mob: +46 (0) 70 311 16 83
E-mail: kerstin.hasselgren@xspray.com

About Xspray Pharma

About Xspray Pharma AB
Xspray Pharma AB (publ) is a pharmaceutical company focused on the development of improved PKIs for cancer treatment, leveraging its proprietary HyNap™ technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma’s shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). For more information about Xspray Pharma AB and its innovative approach to cancer treatment, please visit www.xspraypharma.com.

This information is information that Xspray Pharma AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-03-27 08:30 CET.

Attachments

20240327 Xspray Pharma Annual Report 2023 Eng
549300NGRQCNZ3X4L157-2023-12-31-sv (4)